{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:42:55Z","timestamp":1792640575704,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:00:00Z","timestamp":1792627200000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01565-0","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:32:53Z","timestamp":1785169973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2645-8557","authenticated-orcid":false,"given":"Aimaz","family":"Afrough","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1010-4578","authenticated-orcid":false,"given":"Andrew J.","family":"Portuguese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud R.","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Sannareddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danai","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1663-0325","authenticated-orcid":false,"given":"Utkarsh","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hossam M.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2111-2461","authenticated-orcid":false,"given":"Kelley","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"De Menezes Silva Corraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Janakiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Goldsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0693-4202","authenticated-orcid":false,"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3678-2805","authenticated-orcid":false,"given":"Lindsay","family":"Fogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Zolotov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5768-9396","authenticated-orcid":false,"given":"Megan M.","family":"Herr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-2703","authenticated-orcid":false,"given":"Hamza","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9182-3931","authenticated-orcid":false,"given":"Jeries","family":"Kort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8206-8919","authenticated-orcid":false,"given":"Susan","family":"Bal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Joiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer","family":"AL Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-6316","authenticated-orcid":false,"given":"Adeel M.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3781-5441","authenticated-orcid":false,"given":"Rahul","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaela","family":"Cassano Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3288-7614","authenticated-orcid":false,"given":"Surbhi","family":"Sidana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-085X","authenticated-orcid":false,"given":"Masooma Shifa","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekha","family":"Mikkilineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Hosoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4547-7534","authenticated-orcid":false,"given":"Shebli","family":"Atrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8066-6781","authenticated-orcid":false,"given":"Cindy","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4268-2698","authenticated-orcid":false,"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-5507","authenticated-orcid":false,"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4124-4277","authenticated-orcid":false,"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0639-3768","authenticated-orcid":false,"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciara","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6531-9595","authenticated-orcid":false,"given":"Larry D.","family":"Anderson Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter M.","family":"Voorhees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda-Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1565_CR1","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1182\/blood.2024024590","volume":"144","author":"M John","year":"2024","unstructured":"John M, Helal M, Duell J, Mattavelli G, Stanojkovska E, Afrin N, et al. Spatial transcriptomics reveals profound subclonal heterogeneity and T-cell dysfunction in extramedullary myeloma. Blood. 2024;144:2121\u201335. https:\/\/doi.org\/10.1182\/blood.2024024590.","journal-title":"Blood"},{"key":"1565_CR2","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ajh.27469","volume":"99","author":"Y Qi","year":"2024","unstructured":"Qi Y, Li H, Qi K, Zhu F, Cheng H, Chen W, et al. Clinical outcomes and microenvironment profiling in relapsed\/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapy. Am J Hematol. 2024;99:2286\u201395. https:\/\/doi.org\/10.1002\/ajh.27469.","journal-title":"Am J Hematol"},{"key":"1565_CR3","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1158\/1078-0432.Ccr-19-0694","volume":"26","author":"D Ryu","year":"2020","unstructured":"Ryu D, Kim SJ, Hong Y, Jo A, Kim N, Kim HJ, et al. Alterations in the transcriptional programs of myeloma cells and the microenvironment during extramedullary progression affect proliferation and immune evasion. Clin Cancer Res. 2020;26:935\u201344. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-0694.","journal-title":"Clin Cancer Res"},{"key":"1565_CR4","doi-asserted-by":"publisher","unstructured":"Boulogeorgou K, Papaioannou M, Chatzileontiadou S, Georgiou E, Fola A, Tzorakoleftheraki SE et al. Unveiling extramedullary myeloma immune microenvironment: a systematic review. Cancers. 2025;17 https:\/\/doi.org\/10.3390\/cancers17071081","DOI":"10.3390\/cancers17071081"},{"key":"1565_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3","volume":"12","author":"J Blad\u00e9","year":"2022","unstructured":"Blad\u00e9 J, Beksac M, Caers J, Jurczyszyn A, von Lilienfeld-Toal M, Moreau P, et al. Extramedullary disease in multiple myeloma: a systematic literature review. Blood Cancer J. 2022;12:45. https:\/\/doi.org\/10.1038\/s41408-022-00643-3.","journal-title":"Blood Cancer J"},{"key":"1565_CR6","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/ajh.70138","volume":"101","author":"S Kumar","year":"2026","unstructured":"Kumar S, Richter J, Usmani SZ, Cohen YC, Ye JC, Mateos MV, et al. Extramedullary disease-achilles heel in myeloma? Am J Hematol. 2026;101:521\u201336. https:\/\/doi.org\/10.1002\/ajh.70138.","journal-title":"Am J Hematol"},{"key":"1565_CR7","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.celrep.2015.06.059","volume":"12","author":"AM Roccaro","year":"2015","unstructured":"Roccaro AM, Mishima Y, Sacco A, Moschetta M, Tai YT, Shi J, et al. CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation. Cell Rep. 2015;12:622\u201335. https:\/\/doi.org\/10.1016\/j.celrep.2015.06.059.","journal-title":"Cell Rep"},{"key":"1565_CR8","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/s41375-024-02206-w","volume":"38","author":"T Jelinek","year":"2024","unstructured":"Jelinek T, Zihala D, Sevcikova T, Anilkumar Sithara A, Kapustova V, Sahinbegovic H, et al. Beyond the marrow: insights from comprehensive next-generation sequencing of extramedullary multiple myeloma tumors. Leukemia. 2024;38:1323\u201333. https:\/\/doi.org\/10.1038\/s41375-024-02206-w.","journal-title":"Leukemia"},{"key":"1565_CR9","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1182\/bloodadvances.2025016619","volume":"9","author":"S Zanwar","year":"2025","unstructured":"Zanwar S, Novak J, Gonsalves W, Howe M, Braggio E, Rajkumar SV, et al. Extramedullary myeloma is genomically complex and characterized by near-universal MAPK pathway alterations. Blood Adv. 2025;9:3979\u201387. https:\/\/doi.org\/10.1182\/bloodadvances.2025016619.","journal-title":"Blood Adv"},{"key":"1565_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01190-9","volume":"14","author":"R Nakamoto-Matsubara","year":"2024","unstructured":"Nakamoto-Matsubara R, Nardi V, Horick N, Fukushima T, Han RS, Shome R, et al. Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma. Blood Cancer J. 2024;14:224. https:\/\/doi.org\/10.1038\/s41408-024-01190-9.","journal-title":"Blood Cancer J"},{"key":"1565_CR11","doi-asserted-by":"publisher","first-page":"6263","DOI":"10.1007\/s00277-025-06705-3","volume":"104","author":"PM Voorhees","year":"2025","unstructured":"Voorhees PM, Kumar S, Usmani SZ, Ye JC, Cohen YC, Scott E, et al. Outcomes in patients with relapsed\/refractory multiple myeloma with extramedullary disease: a meta-analysis. Annals of Hematology. 2025;104:6263\u201374. https:\/\/doi.org\/10.1007\/s00277-025-06705-3.","journal-title":"Annals of Hematology"},{"key":"1565_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01414-6","volume":"16","author":"A Afrough","year":"2025","unstructured":"Afrough A, Dima D, Razzo B, Goel U, Sannareddy A, Pasvolsky O, et al. The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience. Blood Cancer J. 2025;16:12. https:\/\/doi.org\/10.1038\/s41408-025-01414-6.","journal-title":"Blood Cancer J"},{"key":"1565_CR13","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1\u20132 study. The Lancet Haematology. 2025;12:e269\u2013e281. https:\/\/doi.org\/10.1016\/S2352-3026(24)00385-5.","journal-title":"The Lancet Haematology"},{"key":"1565_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00277-016-2847-z","volume":"96","author":"S Mangiacavalli","year":"2017","unstructured":"Mangiacavalli S, Pompa A, Ferretti V, Klersy C, Cocito F, Varettoni M, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96:73\u201380. https:\/\/doi.org\/10.1007\/s00277-016-2847-z.","journal-title":"Ann Hematol"},{"key":"1565_CR15","doi-asserted-by":"publisher","first-page":"2887","DOI":"10.1038\/s41375-020-0921-y","volume":"34","author":"CJ Neuse","year":"2020","unstructured":"Neuse CJ, Lomas OC, Schliemann C, Shen YJ, Manier S, Bustoros M, et al. Genome instability in multiple myeloma. Leukemia. 2020;34:2887\u201397. https:\/\/doi.org\/10.1038\/s41375-020-0921-y.","journal-title":"Leukemia"},{"key":"1565_CR16","doi-asserted-by":"publisher","unstructured":"Li, S, Liu, J, Peyton, M, Lazaro, O, McCabe, SD, Huang, X et al. Multiple myeloma insights from single-cell analysis: clonal evolution, the microenvironment, therapy evasion, and clinical implications. Cancers. 2025;17 https:\/\/doi.org\/10.3390\/cancers17040653","DOI":"10.3390\/cancers17040653"},{"key":"1565_CR17","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/jco-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International myeloma society\/international myeloma working group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351. https:\/\/doi.org\/10.1200\/jco-24-01893.","journal-title":"J Clin Oncol"},{"key":"1565_CR18","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6.","journal-title":"Lancet Oncol"},{"key":"1565_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01314-9","volume":"15","author":"D Dima","year":"2025","unstructured":"Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, et al. Outcomes of teclistamab in patients with relapsed\/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J. 2025;15:111. https:\/\/doi.org\/10.1038\/s41408-025-01314-9.","journal-title":"Blood Cancer J"},{"key":"1565_CR20","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.3324\/haematol.2023.284436","volume":"109","author":"M Forsberg","year":"2024","unstructured":"Forsberg M, Beltran S, Goldfinger M, Janakiram M, Kalbi D, Verma A, et al. Phenomenon of tumor flare with talquetamab in a patient with extramedullary myeloma. Haematologica. 2024;109:2368\u201371. https:\/\/doi.org\/10.3324\/haematol.2023.284436.","journal-title":"Haematologica"},{"key":"1565_CR21","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1097\/rlu.0000000000004588","volume":"48","author":"B Jamet","year":"2023","unstructured":"Jamet B, Bodet-Milin C, Moreau P, Kraeber-Bod\u00e9r\u00e9 F, Touzeau C. 2-[18 F]FDG PET\/CT flare-up phenomena following T-cell engager bispecific antibody in multiple myeloma. Clin Nucl Med. 2023;48:e230\u2013e231. https:\/\/doi.org\/10.1097\/rlu.0000000000004588.","journal-title":"Clin Nucl Med"},{"key":"1565_CR22","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s11135-006-9018-6","volume":"41","author":"RM O\u2019brien","year":"2007","unstructured":"O\u2019brien RM. A caution regarding rules of thumb for variance inflation factors. Qual Quantity. 2007;41:673\u201390. https:\/\/doi.org\/10.1007\/s11135-006-9018-6.","journal-title":"Qual Quantity"},{"key":"1565_CR23","unstructured":"FDA. FDA grants accelerated approval to talquetamab-tgvs for relapsed or refractory multiple myeloma, https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-talquetamab-tgvs-relapsed-or-refractory-multiple-myeloma (2023)."},{"key":"1565_CR24","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1001\/jamaoncol.2023.4504","volume":"10","author":"M Ventin","year":"2024","unstructured":"Ventin M, Cattaneo G, Maggs L, Arya S, Wang X, Ferrone CR. Implications of high tumor burden on chimeric antigen receptor t-cell immunotherapy: a review. JAMA Oncol. 2024;10:115\u201321. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4504.","journal-title":"JAMA Oncol"},{"key":"1565_CR25","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.Ccr-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij CPM, O\u2019Neill CA, Broekmans MEC, Frerichs KA, Bruins WSC, Duetz C, et al. T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin Cancer Res. 2024;30:3006\u201322. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-3333.","journal-title":"Clin Cancer Res"},{"key":"1565_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.imlet.2019.05.012","volume":"211","author":"K Yamamoto","year":"2019","unstructured":"Yamamoto K, Kitawaki T, Sugimoto N, Fujita H, Kawase Y, Takaori-Kondo A, et al. Anti-inflammatory modulation of human myeloid-derived dendritic cell subsets by lenalidomide. Immunol Lett. 2019;211:41\u201348. https:\/\/doi.org\/10.1016\/j.imlet.2019.05.012.","journal-title":"Immunol Lett"},{"key":"1565_CR27","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJMoa2023325","volume":"383","author":"L Ostendorf","year":"2020","unstructured":"Ostendorf L, Burns M, Durek P, Heinz GA, Heinrich F, Garantziotis P, et al. Targeting CD38 with daratumumab in refractory systemic lupus erythematosus. N Engl J Med. 2020;383:1149\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2023325.","journal-title":"N Engl J Med"},{"key":"1565_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.649441","volume":"12","author":"A Zaninoni","year":"2021","unstructured":"Zaninoni A, Giannotta JA, Gall\u00ec A, Artuso R, Bianchi P, Malcovati L, et al. The immunomodulatory effect and clinical efficacy of daratumumab in a patient with cold agglutinin disease. Front Immunol. 2021;12:649441. https:\/\/doi.org\/10.3389\/fimmu.2021.649441.","journal-title":"Front Immunol"},{"key":"1565_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M, Arampatzi P, Duell J, Heidemeier A, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27:616\u20139. https:\/\/doi.org\/10.1038\/s41591-021-01245-5.","journal-title":"Nat Med"},{"key":"1565_CR30","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee H, Ahn S, Maity R, Leblay N, Ziccheddu B, Truger M, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29:2295\u2013306. https:\/\/doi.org\/10.1038\/s41591-023-02491-5.","journal-title":"Nat Med"},{"key":"1565_CR31","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood.2023023557","volume":"144","author":"RS Firestone","year":"2024","unstructured":"Firestone RS, Socci ND, Shekarkhand T, Zhu M, Qin WG, Hultcrantz M, et al. Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma. Blood. 2024;144:402\u20137. https:\/\/doi.org\/10.1182\/blood.2023023557.","journal-title":"Blood"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.seminhematol.2025.12.004","volume":"62","author":"E Sezer","year":"2025","unstructured":"Sezer E, Lee S, Chung J. BCMA biology and therapeutic targeting in multiple myeloma: from ligand signaling to antigen escape. Semin Hematol. 2025;62:267\u201378. https:\/\/doi.org\/10.1053\/j.seminhematol.2025.12.004.","journal-title":"Semin Hematol"},{"key":"1565_CR33","doi-asserted-by":"publisher","first-page":"e693","DOI":"10.1016\/s2352-3026(24)00186-8","volume":"11","author":"N van de Donk","year":"2024","unstructured":"van de Donk N, Chari A, Mateos MV. Mechanisms of resistance against T-cell engaging bispecific antibodies in multiple myeloma: implications for novel treatment strategies. Lancet Haematol. 2024;11:e693\u2013e707. https:\/\/doi.org\/10.1016\/s2352-3026(24)00186-8.","journal-title":"Lancet Haematol"},{"key":"1565_CR34","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1056\/NEJMoa2303194","volume":"389","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ, Ramasamy K, et al. Mezigdomide plus dexamethasone in relapsed and refractory multiple myeloma. N Engl J Med. 2023;389:1009\u201322. https:\/\/doi.org\/10.1056\/NEJMoa2303194.","journal-title":"N Engl J Med"},{"key":"1565_CR35","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.3324\/haematol.2025.287545","volume":"110","author":"M Broughton","year":"2025","unstructured":"Broughton M, Bhatta S, Sonali D, Bumma N, Khan AM, Devarakonda S, et al. Comprehensive evaluation of disease characteristics and outcomes of patients with extramedullary multiple myeloma in the modern era. Haematologica. 2025;110:3053\u201364. https:\/\/doi.org\/10.3324\/haematol.2025.287545.","journal-title":"Haematologica"},{"key":"1565_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-13309-z","volume":"24","author":"D Liang","year":"2024","unstructured":"Liang D, Yan Y, Bai S, Xu W, Wang Q, Feng D, et al. The impact of high-risk cytogenetic abnormalities in extramedullary multiple myeloma in the era of novel agents: insights from a multicenter study. BMC Cancer. 2024;24:1551. https:\/\/doi.org\/10.1186\/s12885-024-13309-z.","journal-title":"BMC Cancer"},{"key":"1565_CR37","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1002\/ajh.27023","volume":"98","author":"S Zanwar","year":"2023","unstructured":"Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma. Am J Hematol. 2023;98:1540\u20139. https:\/\/doi.org\/10.1002\/ajh.27023.","journal-title":"Am J Hematol"},{"key":"1565_CR38","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari A, Minnema MC, Berdeja JG, Oriol A, van de Donk N, Rodr\u00edguez-Otero P, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387:2232\u201344. https:\/\/doi.org\/10.1056\/NEJMoa2204591.","journal-title":"N Engl J Med"},{"key":"1565_CR39","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/s2352-3026(24)00385-5","volume":"12","author":"A Chari","year":"2025","unstructured":"Chari A, Touzeau C, Schinke C, Minnema MC, Berdeja JG, Oriol A, et al. Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. Lancet Haematol. 2025;12:e269\u2013e281. https:\/\/doi.org\/10.1016\/s2352-3026(24)00385-5.","journal-title":"Lancet Haematol"},{"key":"1565_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03409-y","author":"H Einsele","year":"2025","unstructured":"Einsele H, Moreau P, Bahlis N, Bhutani M, Vincent L, Karlin L, et al. Comparative efficacy of talquetamab vs. real-world physician\u2019s choice of treatment in triple-class-exposed relapsed\/refractory multiple myeloma: updated analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent. Adv Ther. 2025. https:\/\/doi.org\/10.1007\/s12325-025-03409-y.","journal-title":"Adv Ther"},{"key":"1565_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"1565_CR42","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.clml.2025.03.014","volume":"25","author":"P Moreau","year":"2025","unstructured":"Moreau P, Mateos MV, Goldschmidt H, Garcia MEG, Besemer B, Perez MSG, et al. Outcomes of patients with extramedullary disease in triple-class exposed relapsed\/refractory multiple myeloma from the pooled LocoMMotion and MoMMent studies. Clin Lymphoma Myeloma Leuk. 2025;25:646\u2013e641. https:\/\/doi.org\/10.1016\/j.clml.2025.03.014.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1565_CR43","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/jco.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Berdeja JG, Agha M, Cohen AD, Hari P, et al. Ciltacabtagene Autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J Clin Oncol. 2023;41:1265\u201374. https:\/\/doi.org\/10.1200\/jco.22.00842.","journal-title":"J Clin Oncol"},{"key":"1565_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1182\/blood.2024025945","volume":"145","author":"S Sidana","year":"2025","unstructured":"Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma. Blood. 2025;145:85\u201397. https:\/\/doi.org\/10.1182\/blood.2024025945.","journal-title":"Blood"},{"key":"1565_CR45","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","volume":"17","author":"S Zanwar","year":"2024","unstructured":"Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, et al. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol. 2024;17:42 https:\/\/doi.org\/10.1186\/s13045-024-01555-4.","journal-title":"J Hematol Oncol"},{"key":"1565_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-026-01477-z","author":"AJ Portuguese","year":"2026","unstructured":"Portuguese AJ, Davis JA, Raza S, Castaneda Puglianini O, Freeman C, Alsina M, et al. Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer Journal. 2026. https:\/\/doi.org\/10.1038\/s41408-026-01477-z.","journal-title":"Blood Cancer Journal"},{"key":"1565_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01386-7","volume":"15","author":"S Al Hadidi","year":"2025","unstructured":"Al Hadidi S, Szabo A, Mohan Lal B, Bag A, Zhen S, Ogunsesan Y, et al. Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer Journal. 2025;15:196. https:\/\/doi.org\/10.1038\/s41408-025-01386-7.","journal-title":"Blood Cancer Journal"},{"key":"1565_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M, Sebag M, Kim K, Min CK, et al. Talquetamab plus teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2025;392:138\u201349. https:\/\/doi.org\/10.1056\/NEJMoa2406536.","journal-title":"N Engl J Med"},{"key":"1565_CR49","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/jco-25-00760","volume":"43","author":"S Jagannath","year":"2025","unstructured":"Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, et al. Long-Term (\u22655-Year) remission and survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 patients with relapsed\/refractory multiple myeloma. J Clin Oncol. 2025;43:2766\u201371. https:\/\/doi.org\/10.1200\/jco-25-00760.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01565-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:27:15Z","timestamp":1792639635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01565-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01565-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AA reports Advisory role for Karyopharm, BMS, Sanofi, Johnson & Johnson, Pfizer, and research funding from Abbvi, Adaptive Biotech, K36-therapeutics, Johnson & Johnson, Regeneron Pharmaceuticals. DD reports Advisory role for Karyopharm, Caribou Biosciences, Legend Biotech, KITE, Pfizer. CV reports honorarium from Sanofi, Johnson & Johnson, and research funding from K36-therapeutics, Johnson & Johnson, Kite\/Arcellx. CJF reports consulting: Johnson & Johnson; Research: Johnson & Johnson, Regeneron; ownership of publicly traded stock: Affimed. RB reports consulting: Adaptive Biotech, Arcellx, BMS, Caribou Biosciences, Genentech, Gilead, Johnson & Johnson, Karyopharm, Legend Biotech, Pfizer, Sanofi, SparkCures; Research: Abbvie, BMS, Gilead, Johnson & Johnson, Karyopharm, Novartis, Pack Health, Prothena, Sanofi. RB reports research funding to his institution from BMS, Janssen, Karyopharm, Regeneron, and abbvie as well as consulting from Janssen, Sanofi. JK reports consulting: GPCR, Johnson & Johnson, Prothena, Legend Biotech, Kite, Sanofi, Pfizer; research: Prothena, Ascentage, Johnson & Johnson, Karyopharm, GPCR. SG reports honoraria from BMS, Johnson & Johnson. JAD reports consultancy for BMS, Johnson & Johnson; speaker\u2019s bureau for GSK, Johnson & Johnson. MRG advisory board to BMS and Arcellx. FA reports advisor role and speaker for BMS, Celgene, Caribou Biosciences; research funding from Allogene Therapeutic, Celgene, GlaxoSmithKline, Bristol Myers Squibb, and Caribou Biosciences. LS reports consulting for Johnson & Johnson, BMS, Novartis. AG-C reports advisory board for Sanofi, Johnson & Johnson, Pfizer, Regeneron, BMS, Cellectar, Kite, GSK. Speaker bureau for Sanofi, Johnson & Johnson, Pfizer, Amgen, GSK, Regeneron. AJP reports consulting from Karyopharm, Capvision. HH reports consulting for Johnson & Johnson; speaker bureaus for Johnson & Johnson, Karyopharm. LM reports advisory board with Legend Biotech and BioLineRx. OCP reports consulting from Legend Biotech Inc, BMS, and Johnson & Johnson. SR reports advisory board from Pfizer, Prothena Biosciences, and kite, and research from Nexcella Inc, Poseida and Johnson & Johnson. SH reports receiving consulting fees from Johnson & Johnson and Sanofi. YL reports consulting from Johnson & Johnson, Legend, Celgene, Sanofi, BMS, Pfizer, Regeneron, Genentech, NexImmune, Caribou; research funding from Johnson & Johnson, Celgene, BMS. SA reports research funding: GSK, Amgen, Karyopharm; honoraria: Johnson & Johnson, and consultancy with Pfizer, Sanofi. DS reports consulting from Sanofi, Johnson & Johnson, Pfizer, BMS, GlaxoSmithKline, Legend Biotech, Bioline, AstraZeneca, Arcellx, Abbvie, Genentech, Opna Bio, and research from Pfizer. PMV reports consultancy for Abbvie, AstraZeneca; BMS, Karyopharm, Lava Therapeutics, Sanofi; Regeneron, Johnson & Johnson, GSK; research funding: Abbvie, GSK, Johnson & Johnson, Regeneron. FLL reports Scientific Advisory Role\/Consulting Fees: A2, Adaptive Biotechnologies, Adaptimmune, Allogene, Amgen, Astra-Zeneca, Bluebird Bio, BMS, Calibr, Caribou, EcoR1, Gerson Lehrman Group (GLG), Iovance, Kite Pharma, Janssen, Legend Biotech, Miltenyi, Novartis, Sana, Pfizer, Poseida. Data Safety Monitoring Board: Data and Safety Monitoring Board for the NCI Safety Oversight CAR T-cell Therapies Committee. Research Contracts or Grants to my Institution for Service: 2SeventyBio (Institutional), Allogene (Institutional), BMS (Institutional), Incyte (Institutional), Kite Pharma (Institutional), Leukemia and Lymphoma Society Scholar in Clinical Research (PI: Locke), Mark Foundation, National Cancer Institute, Patents, Royalties, Other Intellectual Property: Several patents held by the institution in my name (unlicensed) in the field of cellular immunotherapy. Education or Editorial Activity: Aptitude Health, ASH, ASTCT, Clinical Care Options Oncology, Society for Immunotherapy of Cancer. SS is supported by Leukemia Lymphoma Society (Blood Cancer United) Scholar in Clinical Research Award 426 (SS, Grant #2353-26), and reports advisory role for Johnson & Johnson, BMS, Legend, Arcellx, Kite, Genentech, Roche, Sanofi, Pfizer, Takeda, Kite, Bioline, AbbVie, Regeneron, Cell Centric and research funding from Janssen, Magenta Therapeutics, Allogene Therapeutics, Novartis, Kite and BMS. KKP reports advisory\/Consultancy from Johnson and Johnson, BMS, Legend Bioteh, Pfizer, Takeda, Sanofi, Oricel, Kite, Arcellx, Caribou Sciences, Novartis, Takeda, Regeneron, Poseida, DKH reports research funding from Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma\/Gilead Sciences, AstraZeneca, and Karyopharm and supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center. LJC reports Honoraria from Amgen, Bristol-Myers-Squibb, AbbVie, Pfizer, Johnson & Johnson, Adaptive Biotechnologies, Sanofi, Genentech\/Roche), and Research Funding from Amgen, Bristol-Myers-Squibb, Johnson & Johnson, AbbVie, Caribou, Gracell, Genentech\/Roche. LDA reports consulting: Johnson & Johnson, Celgene, BMS, Amgen, GSK, AbbVie, Beigene, Cellectar, Sanofi, Prothena, Pfizer, Karyopharm, Arcellx. Research: BMS, Celgene, Johnson & Johnson, Abbvie. The rest of the authors have no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"This multi-center study was approved by the respective institutions\u2019 Institutional Review Board.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"188"}}